Characterization of DCTN1 genetic variability in neurodegeneration
Abstract
Objective: Recently, mutations in DCTN1 were found to cause Perry syndrome, a parkinsonian disorder with TDP-43-positive pathology. Previously, mutations in DCTN1 were identified in a family with lower motor neuron disease, in amyotrophic lateral sclerosis (ALS), and in a family with ALS/frontotemporal dementia (FTD), suggesting a central role for DCTN1 in neurodegeneration.
Methods: In this study we sequenced all DCTN1 exons and exon-intron boundaries in 286 samples diagnosed with Parkinson disease (PD), frontotemporal lobar degeneration (FTLD), or ALS.
Results: This analysis revealed 36 novel variants (9 missense, 5 silent, and 22 noncoding). Segregation analysis in families and association studies in PD, FTLD, and ALS case–control series did not identify any variants segregating with disease or associated with increased disease risk.
Conclusions: This study suggests that pathogenic mutations in DCTN1 are rare and do not play a common role in the development of Parkinson disease, frontotemporal lobar degeneration, or amyotrophic lateral sclerosis.
Get full access to this article
View all available purchase options and get full access to this article.
Supplementary Material
REFERENCES
1.
De Vos KJ, Grierson AJ, Ackerley S, Miller CC. Role of axonal transport in neurodegenerative diseases. Annu Rev Neurosci 2008;31:151–173.
2.
Chevalier-Larsen E, Holzbaur EL. Axonal transport and neurodegenerative disease. Biochim Biophys Acta 2006;1762:1094–1108.
3.
Puls I, Jonnakuty C, LaMonte BH, et al. Mutant dynactin in motor neuron disease. Nat Genet 2003;33:455–456.
4.
Puls I, Oh SJ, Sumner CJ, et al. Distal spinal and bulbar muscular atrophy caused by dynactin mutation. Ann Neurol 2005;57:687–694.
5.
Levy JR, Sumner CJ, Caviston JP, et al. A motor neuron disease-associated mutation in p150Glued perturbs dynactin function and induces protein aggregation. J Cell Biol 2006;172:733–745.
6.
Munch C, Sedlmeier R, Meyer T, et al. Point mutations of the p150 subunit of dynactin (DCTN1) gene in ALS. Neurology 2004;63:724–726.
7.
Munch C, Rosenbohm A, Sperfeld AD, et al. Heterozygous R1101K mutation of the DCTN1 gene in a family with ALS and FTD. Ann Neurol 2005;58:777–780.
8.
Wider C, Wszolek ZK. Rapidly progressive familial parkinsonism with central hypoventilation, depression and weight loss (Perry syndrome): a literature review. Parkinsonism Relat Disord 2008;14:1–7.
9.
Farrer M, Hulihan MM, Kachergus JM, et al. DCTN1 mutations in Perry syndrome. Nat Genet 2008;41:163–165.
10.
Wider C, Dickson DW, Stoessl AJ, et al. Pallidonigral TDP-43 pathology in Perry syndrome. Parkinsonism Relat Disord 2009;15:281–286.
11.
Mata IF, Kachergus JM, Taylor JP, et al. Lrrk2 pathogenic substitutions in Parkinson’s disease. Neurogenetics 2005;6:171–177.
12.
Dixit R, Levy JR, Tokito M, Ligon LA, Holzbaur EL. Regulation of dynactin through the differential expression of p150Glued isoforms. J Biol Chem 2008;283:33611–33619.
13.
Culver-Hanlon TL, Lex SA, Stephens AD, Quintyne NJ, King SJ. A microtubule-binding domain in dynactin increases dynein processivity by skating along microtubules. Nat Cell Biol 2006;8:264–270.
14.
Weisbrich A, Honnappa S, Jaussi R, et al. Structure-function relationship of CAP-Gly domains. Nat Struct Mol Biol 2007;14:959–967.
15.
Hayashi I, Plevin MJ, Ikura M. CLIP170 autoinhibition mimics intermolecular interactions with p150Glued or EB1. Nat Struct Mol Biol 2007;14:980–981.
16.
Schroer TA. Dynactin. Annu Rev Cell Dev Biol 2004;20:759–779.
Information & Authors
Information
Published In
Copyright
© 2009.
Publication History
Published online: June 8, 2009
Published in issue: June 9, 2009
Authors
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- The role of autophagy in the pathogenesis and treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), Autophagy Reports, 4, 1, (2025).https://doi.org/10.1080/27694127.2025.2474796
- Abundant transcriptomic alterations in the human cerebellum of patients with a C9orf72 repeat expansion, Acta Neuropathologica, 147, 1, (2024).https://doi.org/10.1007/s00401-024-02720-2
- Wild-Type DCTN1 Suppresses the Aggregation of DCTN1 Mutants Associated with Perry Disease, Biological and Pharmaceutical Bulletin, 47, 1, (253-258), (2024).https://doi.org/10.1248/bpb.b23-00828
- Studies of Genetic and Proteomic Risk Factors of Amyotrophic Lateral Sclerosis Inspire Biomarker Development and Gene Therapy, Cells, 12, 15, (1948), (2023).https://doi.org/10.3390/cells12151948
- Unraveling Molecular and Genetic Insights into Neurodegenerative Diseases: Advances in Understanding Alzheimer’s, Parkinson’s, and Huntington’s Diseases and Amyotrophic Lateral Sclerosis, International Journal of Molecular Sciences, 24, 13, (10809), (2023).https://doi.org/10.3390/ijms241310809
- Primary lateral sclerosis, Motor System Disorders, Part II: Spinal Cord, Neurodegenerative, and Cerebral Disorders and Treatment, (89-99), (2023).https://doi.org/10.1016/B978-0-323-98817-9.00021-1
- Neurodegenerative Diseases: From Dysproteostasis, Altered Calcium Signalosome to Selective Neuronal Vulnerability to AAV-Mediated Gene Therapy, International Journal of Molecular Sciences, 23, 22, (14188), (2022).https://doi.org/10.3390/ijms232214188
- Perry Syndrome with a Novel Mutation and a Rare Presentation, Annals of Indian Academy of Neurology, 25, 4, (703-706), (2022).https://doi.org/10.4103/aian.aian_890_21
- Therapeutic Approaches to Amyotrophic Lateral Sclerosis from the Lab to the Clinic, Current Drug Metabolism, 23, 3, (200-222), (2022).https://doi.org/10.2174/1389200223666220310113110
- New perspectives on cytoskeletal dysregulation and mitochondrial mislocalization in amyotrophic lateral sclerosis, Translational Neurodegeneration, 10, 1, (2021).https://doi.org/10.1186/s40035-021-00272-z
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.